Browsing by Author Scott, Andrew M

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancerPavlakis, Nick; Azad, Arun; Chong, Geoff; Dobrovic, Alexander; Fluck, Kate; Gebski, Val; Johns, Terrance G; Mariadason, John M; Price, Timothy; Salemi, R; Scott, Andrew M; Skrinos, Effie; Tebbutt, Niall; Weickhardt, Andrew J; Northern Clinical School: MedicineDual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer, Journal of Clinical Oncology, vol.30, 13, 2012,pp 1505-1512
2015Glycoprotein A33 deficiency: a new model of impaired intestinal epithelial barrier function and inflammatory diseaseBao, Bob Shi San; Buchert, Michael; Burgess, A W; Doggett, Karen; et al, Various; hollande, Frederic; Johnstone, Cameron; Masson, Frederick; Putoczki, Tracy L; Scott, Andrew M; Tebbutt, Niall C; Williams, Benjamin B; School of Medical Sciences: PathologyGlycoprotein A33 deficiency: a new model of impaired intestinal epithelial barrier function and inflammatory disease, Disease Models & Mechanisms, vol.8, 8, 2015,pp 805-815
2015Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancerByth Wilson, Karen; Cummins, Michelle; Lee, Chee Khoon; Simes, Robert John; Asadi, K; Chionh, F; Mariadason, John M; Murone, C; Nagtegaal, ID; Price, Timothy; Punt, Cornelis JA; Scott, Andrew M; Tebbutt, Niall; Weickhardt, Andrew J; Williams, DS; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreVascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer, British Journal of Cancer, vol.113, 1, 2015,pp 37-45